Full history for every metric is available with a Kvantra account
Checkmate Pharmaceuticals, Inc. (CMPI)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -61 | -63 | |||||
| Net profit | $m | - | - | -21 | -28 | -37 | -61 | -63 |
| EPS reported | $ | -2.84 | -2.92 | |||||
| Operating cashflow per share | $ | -2.48 | -2.48 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -2.48 | -2.48 | |||||
| Free cash flow | $m | -54 | -50 | |||||
| Net debt | $m | -51 | -60 | |||||
| Book value equity | $m | 69 | 55 | |||||
| Book value per share | $ | 3.21 | 2.54 | |||||
| Number of shares | m | 21.63 | 21.63 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.89 | 4.13 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -1.16 | -4.51 | |||||
| EV/EBITDA LTM | x | -0.19 | -2.65 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -98.92% | -27.04% | |||||
| FCF Yield | % | -86.54% | -22.18% | |||||
| Quality | ||||||||
| ROE | % | -88.40% | -63.09% | |||||
| ROIC | % | -88.40% | -88.40% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 0.83 | 0.83 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -81.64% | -26.43% | |||||
| Net debt/Equity | x | -0.73 | -1.09 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Checkmate Pharmaceuticals, Inc. is a biotechnology company focused on the clinical development of innovative cancer treatments. Its primary therapeutic candidate, CMP-001, is undergoing Phase II clinical trials. This investigational drug is being evaluated in combination with pembrolizumab for patients with melanoma resistant to PD-1 inhibitors, and alongside nivolumab for PD-1-naïve neoadjuvant melanoma. The company maintains strategic collaborations with pharmaceutical giants Merck KGaA and Pfizer. Established in 2015, its corporate headquarters are located in Cambridge, Massachusetts. Since May 27, 2022, Checkmate Pharmaceuticals, Inc. has operated as a subsidiary of Regeneron Pharmaceuticals, Inc.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Checkmate Pharmaceuticals, Inc. (CMPI)
Checkmate Pharmaceuticals, Inc. is a biotechnology company focused on the clinical development of innovative cancer treatments. Its primary therapeutic candidate, CMP-001, is undergoing Phase II clinical trials. This investigational drug is being evaluated in combination with pembrolizumab for patients with melanoma resistant to PD-1 inhibitors, and alongside nivolumab for PD-1-naïve neoadjuvant melanoma. The company maintains strategic collaborations with pharmaceutical giants Merck KGaA and Pfizer. Established in 2015, its corporate headquarters are located in Cambridge, Massachusetts. Since May 27, 2022, Checkmate Pharmaceuticals, Inc. has operated as a subsidiary of Regeneron Pharmaceuticals, Inc.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free